A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Active, not recruiting · NCT05378425 · Registry updated 2026-04-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cancer, metastatic malignant neoplasm, neoplasm | Active, not recruiting | Phase 1 | 2026-04-30 | NCT05378425 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
| Nectin Therapeutics Ltd | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Hadassah Medical Center | Jerusalem | Israel | 1 |
| Maria Skłodowska-Curie National Research Institute of Oncology | Warsaw | Poland | 2 |
| Ochsner Clinic Foundation | New Orleans | United States | 69 |
| Sheba Medical Center | Ramat Gan | Israel | 1 |
| The University of Texas MD Anderson Cancer Center | Houston | United States | 207 |